(lp0
S'Vivus Inc. stock rises 4.6% after regaining certain commercial rights for ... MarketWatch - Mar 27, 2017 Vivus Inc. VVUS, +0.00% shares rose 4.6% in premarket trade Monday after the company said it would regain the right to commercialize and promote erectile dysfunction drug Stendra in Africa, the Middle East, Turkey and Russia from Sanofi S.A.'
p1
aS'VIVUS, Inc. Reacquires STENDRA  Commercial Rights from Sanofi Marketwired  - Mar 27, 2017 CAMPBELL, CA-- - VIVUS, Inc.  , announced today that it reached an agreement with Sanofi to return the commercial rights for STENDRA in Africa, the Middle East, Turkey and the&nbsp;...'
p2
aS'VIVUS,INC.  Files An 8-K Entry into a Material Definitive Agreement Market Exclusive - Mar 27, 2017 VIVUS, Inc. is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment.'
p3
aS"How VIVUS Inc  Delivered A Better ROE Than Its Industry? Simply Wall St - Mar 8, 2017 Over the past 12 months, VIVUS Inc  generated an ROE of 273.4%, implying the company created 273.4 cents on every dollar of shareholders' invested capital.VIVUS, Inc.  Scheduled to Post Earnings on Wednesday - BNB Daily VIVUS, Inc.  Major Shareholder Sells $180913.00 in Stock - Sports Perspectives"
p4
aS"A Look Ahead For 2 Stocks: VIVUS, Inc. , KBR, Inc.  Post Analyst - 16 hours ago Wall Street is only getting more bullish on the stock, with 1 of analysts who cover VVUS having a buy-equivalent rating. Analysts have placed a $2.8 price target on VIVUS, Inc., suggesting a 154.55% gain from recent close. It's currently trading about ...VIVUS, Inc.  Major Shareholder Sells $208224.00 in Stock - BBNSIs VIVUS, Inc.  ready to Pivot? Share Update - Morgan Research"
p5
aS"Thursday's Market Insights: Apricus Biosciences Inc , VIVUS, Inc. (VVUS ... Smarter Analyst - Mar 9, 2017 Apricus Biosciences Inc  shares are rising by 3% in Thursday's trading on the news that Apricus has completed the sale to Ferring International of its topical cream Vitaros.VIVUS  Posts Strong Profit Growth; Apricus Biosciences  Soars on ... - Galaxy Stocks  Pre-Open Movers 03/09:    Higher;    Lower ... - StreetInsider.com"
p6
aS'VIVUS to Regain Commercial Rights for Stendra from Sanofi Yahoo Finance - 15 hours ago VIVUS, Inc. VVUS recently announced an agreement with Sanofi SNY to reacquire the commercial rights to its erectile dysfunction drug, Stendra , in Africa, the Middle East, Turkey and the Commonwealth of Independent States, including Russia.VIVUS  agree with Sanofi to return commercial rights for STENDRA - Benchmark Monitor'
p7
aS"VIVUS, Inc.  Efforts To Reshape VIVUS' Business Model StockNewsUnion - Mar 9, 2017 VIVUS, Inc.  a biopharma firm advancing and commercializing unique, next-generation therapies to address open medical needs in human health, released its financial report for the quarter and year closed December 2016 and gave a&nbsp;...VIVUS  Beats on Q4 Earnings, Revenues Increase Y/Y - Zacks.com"
p8
aS"Analysts Near-Term outlook: Cemtrex, Inc. , VIVUS, Inc.  The USA Commerce - Mar 24, 2017 Shares of Cemtrex, Inc.  surged 3.47% to $3.28. During the trading on 03/23/2017, Company's stock ranged from $3.37 to $3.14."
p9
aS"Traders Secrets on VIVUS, Inc. , McDermott International, Inc.  StockNewsJournal - Mar 10, 2017 Investors who are keeping close eye on the stock of VIVUS, Inc.  established that the company was able to keep return on investment at -21.11 in the trailing twelve month while Reuters data showed that industry's average stands at 13.50&nbsp;..."
p10
a.